<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099852</url>
  </required_header>
  <id_info>
    <org_study_id>09/B/08</org_study_id>
    <nct_id>NCT01099852</nct_id>
  </id_info>
  <brief_title>Cohort of Patients Infected by an Arbovirus</brief_title>
  <acronym>CARBO</acronym>
  <official_title>Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Antilles-Guyane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are hundred of arbovirus which have been shown to cause disease in humans. Their most&#xD;
      common clinical symptoms are algo-eruptive (dengue, chikungunya, zika), hemorrhagic fever&#xD;
      (dengue, yellow fever, Crimean-Congo hemorrhagic fever), neurological (West Nile, Zika,&#xD;
      dengue, Japanese encephalitis) or arthritic afflictions (Chikungunya, O'nyong nyong). Dengue&#xD;
      is a mosquito-born viral disease caused by 4 different serotypes of virus. Dengue fever (DF)&#xD;
      is defined by the sudden onset of fever with non-specific constitutional symptoms, recovery&#xD;
      occurring spontaneously in 3 to 7 days. The infection can sometimes progress to dengue&#xD;
      hemorrhagic fever (DHF) characterized by a transient increase in vascular permeability&#xD;
      provoking a plasma leakage syndrome. DHF can be complicated by shock and internal hemorrhage.&#xD;
      Other rarer complications include encephalitis, hepatitis, rhabdomyolysis and myocarditis.&#xD;
      There is currently no way of predicting the outcome of DF or DHF and the WHO classification&#xD;
      lacks sufficient sensitivity and specificity to recognize and guide the management of severe&#xD;
      forms of dengue. The pathophysiology of these forms is also poorly known. Since 2000s, the&#xD;
      French West Indies and Guiana have become hyperendemic for dengue with simultaneous&#xD;
      circulation of the 4 serotypes, regular large outbreaks and severe dengue including&#xD;
      fatalities. Chikungunya is a re-emerging virus causing massive epidemics in Africa, in the&#xD;
      Indian Ocean and Southeast Asia. The first autochthonous cases were described in French&#xD;
      Antilles in Nov 2013. The disease typically consists of an acute illness like dengue fever&#xD;
      with abrupt onset of a high-grade fever followed by constitutionals symptoms, poly-arthritis&#xD;
      and skin involvement. Usually, the illness resolves in 4 to 6 weeks. However, severe clinical&#xD;
      forms in early stage may appear and chronic clinical forms as incapacitating arthralgia which&#xD;
      affect 40 to 60% of patients. In France, others arboviruses may cause severe emerging and&#xD;
      re-emerging infectious diseases like Zika or West Nile. In non-immunized population these&#xD;
      emerging diseases may cause outbreaks with specific severe clinical complications. The French&#xD;
      interministerial mission on emerging infectious diseases coordinated by Professor Antoine&#xD;
      Flahault, recommended such studies: large prospective multicenter cohort studies to&#xD;
      characterize severe forms of arbovirus infections to seek predictive factors and to&#xD;
      investigate the pathophysiology of the diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal objective To identify demographic, clinical, biological, virologic, immunologic and&#xD;
      genetic factors associated with or predictive of severe complications of arbovirus infections&#xD;
      (shock, internal bleeding, organ failure, death) in a cohort of children and adults with&#xD;
      confirmed arbovirus infections, in France.&#xD;
&#xD;
      Secondary objective&#xD;
&#xD;
      To identify demographic, clinical, biological, virologic, immunologic and genetic factors&#xD;
      predictive of altered quality of life after confirmed an acute arbovirus infection. Onset of&#xD;
      specific complications:&#xD;
&#xD;
        -  Hemorrhagic fever (dengue: WHO criteria)&#xD;
&#xD;
        -  Neurological disorders (West Nile virus infection, Zika virus infection, Japanese&#xD;
           encephalitis…)&#xD;
&#xD;
        -  Chronic chikungunya (persistent Chronic chikungunya (persistent musculoskeletal symptoms&#xD;
           for more than three months after symptoms onset)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoint is a composite endpoint defined as the occurrence, within 12 weeks of the onset of arbovirosis, of at least 1 of the following events: death or shock or internal bleeding, or failure to one or more organs or systems (brain, heart, lung, liver, kidney, hemostasis). Deaths not attributable directly or indirectly to the arbovirosis in question will not be taken into account.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific complications: Onset of hemorrhagic fever (dengue) Onset of encephalitis or neurological disorders (West Nile virus, Japanese encephalitis, Zika virus) Onset of chronic form (Chikungunya)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The analysis will focus only on patients with biologically confirmed arbovirosis by one of the following exams:&#xD;
RT-PCR plasma (arbovirus), or urine (Zika virus),&#xD;
Research of the NS1 positive antigen (dengue),&#xD;
Significant appearance or increase of the G immunoglobulin directed against the arbovirus in question between an early serum (during the first week following the onset of symptoms) and another taken at least 10 days later</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1377</enrollment>
  <condition>Fever</condition>
  <condition>Dengue</condition>
  <condition>Chikungunya</condition>
  <condition>Zika Virus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological sample collection</intervention_name>
    <description>blood sample collection urine sample cerebrospinal fluid sample</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life Questionnaire EuroQol®</intervention_name>
    <description>Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health Assessment Questionnaire - MDHAQ and RAPID3</intervention_name>
    <description>Questionnaire used at the 3rd month of follow up.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropathic Pain Questionnaire (DN4)</intervention_name>
    <description>Questionnaire used during the follow up</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, plasma, DNA, Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital cohort of children and adults with suspected of infectious by an arbovirus in the&#xD;
        overseas departments and regions and in France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA :&#xD;
&#xD;
          -  Adult, child or newborn with a weight &gt; 2.5 kg the days of enrollment.&#xD;
&#xD;
          -  Consulting a participating hospital center (emergency room, full hospitalization, day&#xD;
             hospitalization, or outpatient visit).&#xD;
&#xD;
          -  Arbovirosis suspected or confirmed biologically: A suspected case of arbovirus&#xD;
             infection is defined by:&#xD;
&#xD;
               -  The combination of clinical and biological signs observed suggestive of&#xD;
                  arbovirosus infection: fever (reported by the patient or family, or documented),&#xD;
                  headache, rash, myalgia, arthralgia, abdominal pain, hemorrhage,&#xD;
                  thrombocytopenia, or&#xD;
&#xD;
               -  Children under 6 years: the report (by family or documented) of a fever on the&#xD;
                  day of enrollment or within 7 previous days, possibly accompanied by a of pain -&#xD;
                  At a patient with a notion of stay in 2 weeks preceding in a zone of arbovirus&#xD;
                  circulation (only for the imported cases)&#xD;
&#xD;
        A case of arbovirus infection confirmed biologically is defined by:&#xD;
&#xD;
          -  RT-PCR arbovirus positive in plasma or urine (Zika virus infection), or by detection&#xD;
             of the NS1 antigen (dengue), or an appearance or an significant increase&#xD;
             (multiplication of the title by four) of the G immunoglobulin directed against&#xD;
             arbovirus in question on an early taken serum (during the first week following the&#xD;
             start of symptoms) and another taken at least 10 days later.&#xD;
&#xD;
          -  Symptom onset within the 7 days before the enrollment visit or within 21 days for&#xD;
             severe forms of the disease.Possibility of follow-up throughout study period. *&#xD;
             Acceptance to participate in the study and in follow-up; informed consent of the&#xD;
             patient (adult and minor in age to express his desire) or a legal representative (for&#xD;
             minors, and patients unable to sign the consent form).&#xD;
&#xD;
        EXCLUSION CRITERIA :&#xD;
&#xD;
          -  No follow-up possible after the first visit&#xD;
&#xD;
          -  Patient or holder of parental authority not registered in the French medical social&#xD;
             security national program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Cabie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Martinique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andre Cabie</last_name>
    <phone>0596552301</phone>
    <email>andre.cabie@chu-fortdefrance.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Denis MALVY</last_name>
      <phone>05.57.82.22.20</phone>
      <email>denis.malvy@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie MATHERON, MD</last_name>
      <phone>01 40 25 78 83</phone>
      <email>Sophie.matheron@bch.ah-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH André Rosemond</name>
      <address>
        <city>Cayenne</city>
        <zip>97300</zip>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Félix Djossou, MD</last_name>
      <email>felix.djossou@ch-cayenne.fr</email>
    </contact>
    <investigator>
      <last_name>Félix Djossou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Pointe à Pitre/Abymes</name>
      <address>
        <city>Pointe à Pitre</city>
        <zip>97261</zip>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline MALLARD</last_name>
      <phone>05 90 89 10 10</phone>
      <email>adeline.mallard@chu-guadeloupe.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97200</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janick Jean-Marie</last_name>
      <phone>592697</phone>
      <phone_ext>0596</phone_ext>
      <email>janick.jean-marie@chu-martinique.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Calmont</last_name>
      <phone>592697</phone>
      <phone_ext>0596</phone_ext>
      <email>isabelle.calmont@chu-martinique.fr</email>
    </contact_backup>
    <investigator>
      <last_name>André CABIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97448</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine BERTOLOTTI</last_name>
      <phone>02 62 35 91 65</phone>
      <email>antoine_bertolotti@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Gabriel Martin</name>
      <address>
        <city>Saint-Paul</city>
        <zip>97866</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémi GIRERD</last_name>
      <phone>0262453030</phone>
      <email>remigirerd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>French Guiana</country>
    <country>Guadeloupe</country>
    <country>Martinique</country>
    <country>Réunion</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dengue</keyword>
  <keyword>fever</keyword>
  <keyword>dengue hemorrhagic fever</keyword>
  <keyword>dengue virus</keyword>
  <keyword>Chikungunya virus</keyword>
  <keyword>Zika Virus</keyword>
  <keyword>Joint pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Chikungunya Fever</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

